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A Human Endogenous Retrovirus K dUTPase Triggers
a TH1, TH17 Cytokine Response: Does It Have a Role
in Psoriasis?
Maria-Eugenia Ariza1,2 and Marshall V. Williams2,3,4
Psoriasis is a chronic inflammatory immune disease of the skin characterized by a complex interplay between
multiple risk genes and their interactions with environmental factors. Recent haplotype analyses have
suggested that deoxyuridine triphosphate nucleotidohydrolase (dUTPase) encoded by a human endogenous
retrovirus K (HERV-K) may be a candidate gene for the psoriasis susceptibility 1 locus. However, no functional
studies have been conducted to determine the role of HERV-K dUTPase in psoriasis. For this purpose, we
constructed an HERV-K dUTPase wild-type sequence, as well as specific mutations reflecting the genotype
characteristic of high- and low-risk haplotypes, purified the recombinant proteins, and evaluated whether they
could modulate innate and/or adaptive immune responses. In this study, we demonstrate that wild-type and
mutant HERV-K dUTPase proteins induce the activation of NF-kB through Toll-like receptor 2, independent of
enzymatic activity. Proteome array studies revealed that treatment of human primary cells with wild-type and
mutant HERV-K dUTPase proteins triggered the secretion of TH1 and TH17 cytokines involved in the formation of
psoriatic plaques, including IL-12p40, IL-23, IL-17, tumor necrosis factor-a, IL-8, and CCL20, in dendritic/
Langerhans-like cells and to a lesser extent in keratinocytes. These data support HERV-K dUTPase as a potential
contributor to psoriasis pathophysiology.
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INTRODUCTION
Psoriasis is an inherited chronic inflammatory disease of the
skin that affects 2–3% of the world’s population. Epidemio-
logical and genetic data suggest that psoriasis development is
a complex process influenced by several risk genes, by
environmental factors such as viral infections, stress, and
trauma, and by the interplay between various cells involved
in innate and adaptive immunity, which are capable of
altering the skin microenvironment through cytokine and
chemokine effector molecules, ultimately resulting in the
differentiation of resident skin cells to form psoriatic lesions
(Lowes et al., 2007; Nickoloff, 2007; Nickoloff et al., 2007;
Nestle et al., 2009).
Of the nine chromosomal loci that have been statistically
associated with psoriasis through classical genome-wide
linkage analysis (Bowcock, 2005; Bowcock and Krueger,
2005), the psoriasis susceptibility 1 (PSORS1) locus, located
in the major histocompatibility complex on chromosome
6p21, has been identified as the strongest genetic determi-
nant of psoriasis, accounting for 35–50% of the heritability of
the disease. Genetic analyses have suggested that HLA-Cw6
is the PSORS1 susceptibility gene (Nair et al., 2000, 2006;
Elder, 2006; Elder et al., 2010), and, although several theories
have been proposed to explain how HLA-Cw6 may trigger
the cytokine/chemokine cascade that is characteristic of
psoriasis (Nickoloff et al., 2007), molecular mechanistic
studies demonstrating it have been a challenge and it still
remains unclear and poorly understood.
Human endogenous retrovirus (HERV) sequences consti-
tute 7–8% of the human genome composition (Rebora, 2005).
Most HERVs have become defective because of recombina-
tion events and by the accumulation of nonsense mutations
ensuring that no protein or viable virus particles are
produced. In contrast, members of the human endogenous
retrovirus K (HERV-K) family comprise less than 1% of the
HERV sequences found in the human genome, but they are
transcriptionally active. Although the replication competent
virus has not been demonstrated in vivo, several HERV-K
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proviruses, such as K113 and K115, have been shown to
contain open reading frames for all genes (Barbulescu et al.,
1999; Mayer et al., 1999; Bannert and Kurth, 2004;
Kim et al., 2004). Perhaps more importantly is the feature
that some HERV-K proviruses exhibit an insertional poly-
morphism (Turner et al., 2001; Belshaw et al., 2005; Moyes
et al., 2005, 2007). There are several reports linking
endogenous retroviruses with numerous autoimmune
diseases including psoriasis (Bannert and Kurth, 2004;
Colmegna and Garry, 2006; Guilhou and Moles, 2008).
However, none of these studies have demonstrated a causal
relationship between virus-encoded proteins and psoriasis
pathogenesis.
It has also been reported that the target region of the
PSORS1 harbors a fragment of HERV-K, which encodes for a
deoxyuridine triphosphate nucleotidohydrolase (dUTPase;
Foerster et al., 2005). dUTPases represent a family of
metalloenzymes that catalyze the hydrolysis of dUTP to
dUMP and pyrophosphate; until recently, their only known
function was preventing dUTP incorporation into DNA by
DNA polymerases (McGeoch, 1990; Mayer and Meese,
2003). Using microarray expression profiling and functional
assays, we recently demonstrated that the monomeric
dUTPase encoded by the Epstein–Barr virus possesses,
functions in innate immunity partly because of the activation
of Toll-like receptor (TLR) 2 and the subsequent modulation
of downstream genes involved in type I IFN (IFNa/b) and
cytokine/chemokine receptor signaling pathways (Glaser
et al., 2006; Waldman et al., 2008; Ariza et al., 2009,
2011). As psoriasis is a chronic inflammatory disease and the
PSORS1 locus may encode a HERV-K dUTPase it is logical to
hypothesize that the HERV-K dUTPase may possess immu-
nomodulatory functions similar to that of the Epstein–Barr
virus-encoded dUTPase. Furthermore, there is accumulating
evidence supporting a potential role of TLRs in psoriasis.
Baker et al. (2003) reported that, although TLR1, 2, and 5 are
constitutively expressed primarily by keratinocytes located in
the basal layer of the epidermis in normal skin, TLR2 was
expressed primarily in keratinocytes located in the upper
epidermis of the lesional skin of psoriasis patients. However,
the biological relevance of the altered TLR expression in
psoriasis remains unknown.
Our hypothesis is that the HERV-K dUTPase protein
triggers the secretion of proinflammatory TH1/TH17 cytokines
and it may contribute to psoriasis pathogenesis by modulating
host innate and adaptive immune responses leading to
immune dysregulation. To address this hypothesis, we
constructed a wild-type DNA sequence of the HERV-K
dUTPase, as well as sequences containing specific mutations
in the gene that reflect the low- and high-risk haplotypes
identified by Foerster et al. (2005); the purified proteins from
these genes were used to determine whether they could
modulate innate and adaptive immune responses leading to
the activation of cytokine/chemokine cascades. In this study,
we demonstrate that the purified HERV-K dUTPase activates
NF-kB in a transgenic human embryonic kidney 293
(HEK293) cell line stably expressing TLR2, but not in wild-
type HEK293 cells. We also demonstrate that treatment of
normal human dendritic/Langerhans-like cells (hDCs), and to
a less extent keratinocytes, with the purified proteins results
in the increased production of cytokines/chemokines IL-1b,
IL-6, Il-8, IL-10, IL-12p40, IL-17, IL-23, transforming growth
factor-a, tumor necrosis factor-a, RANTES, CCL20, and
IFN-g, known to be involved in the formation of psoriatic
plaques. Finally, we demonstrate that the ability of HERV-K
dUTPase to modulate the expression of these cytokines/
chemokines is dependent in part upon the presence or
absence of specific AA residues between P141 and D171.
RESULTS
Cloning of the HERV-K dUTPase gene and mutant construction
To test the hypothesis that the HERV-K dUTPase protein may
be a trigger of psoriasis and/or may contribute to psoriasis
pathogenesis by modulating host innate and adaptive
immune responses leading to immune dysregulation, the
gene encoding HERV-K dUTPase was PCR amplified from
human genomic DNA and cloned into the pTrcHis plasmid
for protein expression. A comparison of DNA sequences from
the low- and high-risk haplotypes, reported by Foerster et al.
(2005), with the wild-type sequence used in this study, and
initially reported by Harris et al. (1997), demonstrates that
there is extensive variation in the C-terminal end of these
proteins. Therefore, in an effort to demonstrate whether the
C-terminal end of the HERV-K dUTPase might be responsible
for promoting immune dysregulation, we also created a series
of point or C-terminal deletion mutations (Figure 1) that were
verified by DNA sequence analysis. Recombinant proteins
were purified as described in Materials and Methods
(Figure 2) and screened for dUTPase activity. None of the
recombinant HERV-K proteins possessed dUTPase activity
when compared with human dUTPase, which was used as a
positive control, even after extended incubation (24 vs.
1 hour for control) and using a 10-fold higher amount of
protein (0.4 vs. 0.04 mg; data not shown).
The HERV-K dUTPase activates TLR2
To explore the possibility that HERV-K dUTPase could be
modulating innate inflammatory immune responses through
TLR2, we investigated whether the HERV-K dUTPase
recombinant proteins could trigger NF-kB activation using
the transgenic HEK293 cell line stably expressing TLR2, as
described previously (Ariza et al., 2009). Briefly, TLR2-
expressing HEK293 cells were transiently transfected with
the NF-kB luciferase reporter gene and transfection control
pRL-TK vectors, followed by treatment with various HERV-K
dUTPase recombinant proteins (10 mgml1), zymosan
(a natural ligand for TLR2), or vehicle control. Human
dUTPase protein was used as a negative control. As demon-
strated in Figure 3, all HERV-K dUTPase recombinant
proteins, except the human dUTPase, induced NF-kB activity,
ranging from 4.5- to 31.5-fold. Interestingly, the recombinant
HERV-K dUTPase mutant protein D142–171, which lacks
the C-terminal 30 amino acids (AAs), caused the highest
level of NF-kB activation (31.5-fold), whereas deleting the
C-terminal 22 AAs impaired the ability of the HERV-K
dUTPase mutant protein D155–171 to activate NF-kB relative
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to that induced by wild-type HERV-K dUTPase protein. No
activation of NF-kB by the wild-type HERV-K dUTPase protein
was observed in HEK293 cells lacking TLR2, which suggests
that NF-kB activation is TLR2 dependent. These data
demonstrate that HERV-K dUTPase proteins activate NF-kB
through TLR2 and that the C-terminal end of the HERV-K
dUTPase protein is important in HERV-K dUTPase-mediated
activation of TLR2 and NF-kB.
HERV-K dUTPase induces cytokine/chemokine secretion in
human primary cells
Recent studies have implicated dendritic cells as being the
central cell mediator in psoriasis as they activate T cells and
produce cytokines/chemokines that amplify the immune
response (Nestle et al., 2009; Zaba et al., 2009; Elder et al.,
2010). To determine whether HERV-K dUTPase proteins
could induce the secretion of cytokines/chemokines in cells
known to be involved in psoriasis (Lowes et al., 2007;
Nickoloff et al., 2007; Hedrick et al., 2009), proteome array
studies were conducted in normal hDCs and keratinocytes.
As shown in Figure 4a–f, treatment of primary hDCs with
wild-type and mutant HERV-K dUTPase recombinant pro-
teins resulted in the increased production of cytokines tumor
necrosis factor-a, IL-23, IL-17, IL-8, IL12p40, and INF-g. In
addition, HERV-K dUTPase proteins also induced the
production of chemokines CCL20 and RANTES. As shown
in Figure 5a–c, there was a modest, but in some cases a
statistically significant, increase in the production of IL-8,
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Figure 1. Deoxyuridine triphosphate nucleotidohydrolase (dUTPase) protein blast alignment. Human endogenous retrovirus K (HERV-K) consensus, as
described by Harris et al. (1997), low-risk haplotype and high-risk haplotype, as described by Foerster et al. (2005), HERV-K dUTPase recombinant proteins
reflecting wild-type, low-risk (N158K and K155R/N158K) and high-risk (N158R and K155G/N158R) haplotypes, as well as various deletion mutations
(D162–171; D155–171, D142–171) used in this study, and the human dUTPase (HudUT). Boxes D-1–D-5 represent the conserved domains of the dUTPase
protein family.
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CCL20, transforming growth factor-a, RANTES, IL-12p40,
IL-1b, IL-17, and IL-23 in the supernatant of HERV-K
dUTPase-treated keratinocytes.
DISCUSSION
Foerster et al. (2005) identified two single-nucleotide poly-
morphisms in the HERV-K dUTPase gene located at the
PSORS1 locus that distinguished low- and high-risk haplo-
types associated with psoriasis and suggested that the
retroviral dUTPase was a candidate gene for the PSORS1
mutation. As a functional role for HERV-K dUTPase in the
pathophysiology of psoriasis has never been established, we
decided to explore whether HERV-K dUTPase possessed
immunomodulatory properties similar to those reported for
the Epstein–Barr virus-encoded dUTPase (Glaser et al., 2006;
Waldman et al., 2008; Ariza et al., 2009).
In this study, we demonstrate that HERV-K dUTPase can
modulate innate and adaptive immune responses in hDCs
and keratinocytes through the activation of TLR2, NF-kB, and
the secretion of proinflammatory TH1/TH17 cytokines, which,
to our knowledge, has not been reported yet. Homotrimeric
and monomeric dUTPases contain five hallmark conserved
sequence domains that are essential for the formation of the
catalytic sites (McGeoch, 1990; Larsson et al., 1996; Mol
et al., 1996; Dauter et al., 1999; Harris et al., 1999;
Tarbouriech et al., 2005). As there is considerable sequence
variation in conserved domain 5 of the b-retrovirus dUT-
Pases, of which HERV-K is a member, when compared with
homotrimeric and monomeric dUTPases from other species
(Harris et al., 1997; Fiser and Vertessy, 2000; Foerster et al.,
2005), we explored the possibility that the C-terminal region
of the HERV-K dUTPase might be important for the
immunomodulatory properties of the protein. The wild-type
and mutant recombinant HERV-K dUTPases used in this
study lacked dUTPase activity, which confirms the original
studies by Harris et al. (1997) and is consistent with structural
and functional data indicating that the highly conserved
phenylalanine residue in conserved domain 5, which is
absent in the HERV-K dUTPases used in this study, is required
for catalytic activity (Mol et al., 1996; Dauter et al., 1999;
Harris et al., 1999; Tarbouriech et al., 2005; Freeman et al.,
2009; Takacs et al., 2009). Various studies of the C-terminal
end of monomeric and homotrimeric dUTPases, containing
conserved domain 5, have demonstrated that this region is
highly flexible because of its role in enzyme catalysis
(Nord et al., 2001; Freeman et al., 2009; Takacs et al.,
2009). The HERV-K dUTPase mutant protein D142–171,
lacking the conserved domains 4 and 5 and the hinge proline
152 (Takacs et al., 2009), caused the highest NF-kB
activation level, which correlated with the greatest induction
of the cytokines/chemokines tested. Conversely, deletion of
the terminal 17 AAs (D155–171) or domain 5 (D162–171)
had little, if any, effect on altering the ability of the protein to
activate NF-kB, relative to the wild type. These results
suggest that either a domain is located between AAs 142 and
154 that inhibits the interaction of HERV-K dUTPase with
TLR2 or, conversely, that deletion of the terminal 30 AAs,
containing conserved domains 4 and 5 and the hinge proline
152, removes the C-terminal flexible arm of the protein,
which could sterically interfere with HERV-K dUTPase
interacting with TLR2. Thus, although additional studies are
required to distinguish these possibilities, our data demon-
strate that the immunomodulatory activity of HERV-K
dUTPase is a distinct function independent from its catalytic
activity and suggest that the C-terminal 30 AAs have a critical
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Figure 3. Human endogenous retrovirus K (HERV-K) deoxyuridine
triphosphate nucleotidohydrolase (dUTPase) modulates innate immunity.
HERV-K dUTPase proteins activate NF-kB through TLR2 in HEK293TLR2-
expressing cells, as determined by luciferase assay. HEK293TLR2 and
wild-type (WT) HEK293 cells were transiently transfected with NF-kB
luciferase reporter plasmid, as described previously (Ariza et al., 2009).
After 24–36hours, cells were treated with various HERV-K dUTPase proteins
(10mgml1), human dUTPase control protein (10 mgml1), and zymosan
(10mgml1, data not shown), or left untreated for 8 hours, and luciferase
reporter gene activity was measured. Data are expressed as the mean fold
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independent experiments. HEK293, human embryonic kidney 293; TLR2,
Toll-like receptor 2.
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role in regulating the immunomodulatory properties of
HERV-K dUTPase.
Blast analysis using the wild-type HERV-K dUTPase gene
demonstrated that there are 14 HERV-K dUTPase sequences
located in the human genome (including the one located at
the PSORS1 locus) that exhibit a high level of homology
(89–99%) to our wild-type DNA sequence. As the wild-type
HERV-K dUTPase gene used in our studies was generated
from human genomic DNA using gene-specific primers, we
cannot state that the amplified HERV-K dUTPase gene
corresponds to the one in the PSORS1 region. Somewhat
interestingly, however, is that these HERV-K dUTPase genes
map to regions previously identified as containing psoriasis
susceptibility genes, as well as other loci identified in various
autoimmune diseases (Johanneson et al., 2002; Bowcock,
2005; Barton et al., 2008; Chang et al., 2008; Hollox et al.,
2008; De Jager et al., 2009; Gateva et al., 2009; Nair et al.,
2009; Zhang et al., 2009; Huffmeier et al., 2010; Stuart
et al., 2010; Sun et al., 2010; Franke et al., 2010; Roberson
and Bowcock, 2010).
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Figure 4. Human endogenous retrovirus K (HERV-K) deoxyuridine triphosphate nucleotidohydrolase (dUTPase) proteins stimulate the secretion of TH1, TH17
cytokines in human dendritic/Langerhans-like cells (hDCs). HERV-K dUTPase proteins differentially induce the secretion of TH1, TH17 cytokines in hDCs
following a 24-hour treatment, as determined by proteome array. (a) IL-23 and IL12p40; (b) tumor necrosis factor (TNF)-a and IL-1b; (c) IL-17 and IFN-g;
(d) CCL20 and RANTES; (e) IL-8 and IL-6; (f) IL-10 and transforming growth factor (TGF)-a. Cytokine/chemokine concentrations represent the average±SD
(pgml1) from two independent experiments (n¼ 4). *Po0.05.
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As we did not use non-lesional or lesional skin from
patients with psoriasis in these studies, it is not possible to
establish a role for HERV-K dUTPase in psoriasis patho-
physiology. However, several studies have reported the
transcriptional activation of HERV sequences in keratinocytes
(Hohenadletal et al., 1999) and in skin from patients with
psoriasis (Bessis et al., 2004; Moles et al., 2005). Further-
more, Foerster et al. (2005) demonstrated that the HERV-K
dUTPase gene located at the PSORS1 locus is expressed in
non-lesional skin and in peripheral blood mononuclear cells
from patients with psoriasis, as well as in skin from healthy
controls. Similarly, whether there are sufficient amounts of
HERV-K dUTPase secreted to initiate the TLR2 cascade
described in this study remains unknown. Although HERV-K
dUTPase was described as having an intracellular location
(Harris et al., 2000), there have not been any additional
studies to determine whether this protein is secreted from
cells. However, there is an accumulating body of evidence
demonstrating that virus-encoded macromolecules are se-
creted in exosomes (Flanagan et al., 2003; Gould et al., 2003;
Pelchen-Matthews et al., 2004; Fang et al., 2007; Balaj et al.,
2011; Izquierdo-Useros et al., 2011; Vallhov et al., 2011),
and defective particles from HERVs have been found in
microvesicle populations (Voisset et al., 2008) and in the
plasma and urine of people with various autoimmune
diseases (Bu¨scher et al., 2005; Dewannieux et al., 2006;
Contreras-Galindo et al., 2008; Blank et al., 2009;
Kakalacheva et al., 2011), including psoriasis (Iversen,
1990). However, additional studies are required to address
this possibility.
The results presented in this study demonstrate that the
stimulation of TLR2 by HERV-K dUTPase results in the
activation of NF-kB signaling pathways and in the secretion
of proinflammatory TH1/TH17 cytokines in both hDCs and
keratinocytes. Interestingly, HERV-K dUTPase-mediated acti-
vation of NF-kB and induction of a TH1/TH17 cytokine
response resemble what is reported to occur in psoriatic skin
(Nair et al., 2009; Zaba et al., 2009). Although additional
studies are needed to determine the expression levels
of the PSORS1 HERV-K dUTPase gene, to demonstrate a
relationship between protein levels in the skin with
disease progression and to correlate mutations in this gene
with disease severity, the results of this study provide
evidence supporting an endogenous retrovirus protein, the
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Figure 5. Effect of human endogenous retrovirus K (HERV-K) deoxyuridine triphosphate nucleotidohydrolase (dUTPase) proteins on TH1, TH17 cytokine
secretion in human primary keratinocytes. HERV-K dUTPase proteins differentially induce the secretion of chemokines and proinflammatory cytokines in
primary keratinocytes following a 24-hour treatment, as determined by proteome array. (a) IL-8 and CCL20; (b) transforming growth factor (TGF)-a and RANTES;
(c) IL-23 and IL-12p40; (d) IL-1b and IL-17. Cytokine/chemokine concentrations represent the average±SD (pgml1) from two independent experiments (n¼ 4).
*Po0.05.
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HERV-K-encoded dUTPase, as a potential contributing factor
in the pathophysiology of psoriasis.
MATERIALS AND METHODS
Amplification of the consensus sequence
PCR amplification of theHERV-K dUTPase gene was performed using
the forward and reverse primer set (125pmol of each), as described
by Harris et al. (1997), human genomic DNA (140 ng; Clontech,
Mountain View, CA), high-fidelity PCR supermix (Invitrogen, Carlsbad,
CA), and the following PCR conditions: denaturation at 94 1C for
3minutes (1 cycle), followed by 35 cycles of 94 1C for 30 seconds,
50 1C for 30 seconds, 72 1C for 1minute, and 1 cycle at 72 1C for
10minutes. Using these PCR conditions, a single DNA fragment of
approximately 521 bp was amplified. The PCR product was purified
using the QIAquick gel extraction kit (QIAGEN), cloned into the
pTrcHis Topo TA expression vector, and the sequence verified by DNA
sequencing analysis at Sequetech Corporation (Mountain View, CA).
Mutant construction
HERV-K dUTPases containing point mutations reflecting the high-
and low-risk haplotypes of psoriasis were generated by site-directed
mutagenesis using the QuikChange Lightning Mutagenesis system
(Stratagene, Santa Clara, CA) and the specific primer sets for the
high-risk (N159R: 50-ATTATTACTCCTGCCTTATATTAAGGTTGGA
AGGAGTGAGATAAAAAGAACAAGAG-30; N159R-antisense: 50-CT
CTTGTTCTTTTTATCTCACTCCTTCCAACCTTAATATAAGGCAGGAG
TAATAAT-30) and low-risk (N159K: 50-TTACTCCTGCCTTATATTAAG
GTTGGAAAGAGTGAGATAAAAAGAAC-30; N159K-antisense: 50-GT
TCTTTTTATCTCACTCTTTCCAACCTTAATATAAGGCAGGAGTAA-30)
haplotypes, following the recommendations of the manufacturer.
The following PCR conditions were used: one cycle at 95 1C for
2minutes, followed by 18 cycles of 95 1C for 20 seconds, 60 1C for
10 seconds, and 68 1C for 2.5minutes, and one cycle at 68 1C
for 5minutes. Amplified products were DpnI digested and screened
for the b-galactosidase (b-galþ ) phenotype. DNA was then purified
and the AA change from asparagine to either arginine (high risk)
or lysine (low risk) was verified by sequence analysis. dUTPases
containing the point mutations reflecting the high- and low-risk
haplotypes have been designated N158R and N158K, respectively.
Dual-point mutation constructs of HERV-K dUTPase (N155R/N158K
and N155R/N158R) were also generated using the forward primer
HERV-K-FL: 50-GGGCTTGTAAGCACTGATTGAGAATTCCTGTCA-30
and the following reverse primer sets: for the high-risk HRDM:
50-CCTTATATTGGGGTGGAAGGAGTGAGATATAGGAATTCAGCT
GC-30; for the low-risk LRDM: 50-CCTTATATTAGGGGTGGAAAG
AGTGAGATATAGGAATTCAGCTGC-30.
HERV-K dUTPase deletion mutations lacking the C-terminal 10
AAs (D162–171), the C-terminal 17 AAs (D155–171), and the
C-terminal 30 AAs (D142–171) were generated by PCR using
HERV-K-FL forward and the reverse HervdutD161: 50-GGGGAAATA
GTGAGATATAGGAATTCAGCTGC-30; HervdutD154: 50-GCTCAAT
TATTACTCCTGCCTTATATTTAGGAATTCACCGG-30; andHervdutD141:
50-ATTCCTTGGAGTGCCAGTCCATGAGAATTCATTG
CT primer sets, respectively.
Purification of proteins
The recombinant HERV-K-encoded dUTPases were purified under
native conditions using HisPur cobalt spin columns (3m1; Pierce,
Rockford, IL). Briefly, E. coli BL21 containing the various expression
constructs was grown in Luria Bertani medium and induced with 1M
isopropyl b-D-1 thiogalactopyranoside, as we have described (Glaser
et al., 2006). Bacteria pellets were collected by low-speed centrifuga-
tion, resuspended in equilibration buffer (0.05M sodium phosphate,
0.3M NaCl, and 0.01M imidazole, pH7.4), and lysed by ultrasonication.
The resulting homogenate was centrifuged (15,000 g, 30minutes at
4 1C), and the supernatant was applied to a HisPur cobalt spin column.
The recombinant proteins were eluted as described by the manufac-
turer. Fractions containing the recombinant protein were combined and
concentrated using Centriprep-10 (Amicon, Beverly, MA). SDS-PAGE
and purity of the protein preparations were determined as we have
described (Studebaker et al., 2005; Glaser et al., 2006). Several
assays were performed to eliminate the possibility that our purified
dUTPase preparations were contaminated with bacterial compo-
nents. High-sensitivity Quant-iT kits (Molecular Probes, Carlsbad,
CA) were used to detect possible DNA and RNA contamination.
The Quant-iT DNA assay can detect double-stranded DNA down
to 1 ngml1, whereas the Quant-iT RNA assay has a detection limit
of 5 ngml1. For the detection of peptidoglycan, the silkworm larvae
plasma assay (Wako Chemicals, Richmond, VA) was used. The
silkworm larvae plasma assay has a detection limit of 10 pgml1
of peptidoglycan. To determine lipopolysaccharide contamination
in our protein preparations, dUTPase preparations were assayed
for lipopolysaccharide using the Limulus Amebocyte Lysate Kit
(BioWhittaker, Walkersville, MD), which can detect endotoxin
concentrations of 0.06 IUml1. The lipopolysaccharide level in
these preparations ranged from 2 to 52 IUml1, with the highest
concentration occurring in the human dUTPase preparation. The
purified dUTPase preparations were stored at 20 1C at stock concen-
trations of 0.4–0.5mgml1. Protein concentration was determined
with the Coomassie Brilliant Blue dye-binding assay (Bio-Rad
Laboratories, Hercules, CA), using BSA as the standard. To
determine whether the HERV-K-encoded dUTPase proteins possessed
functional enzymatic activity, fractions were assayed using a standard
DE81 filter disc assay. The detection limit of this assay, which has been
described previously (Williams, 1985; Glaser et al., 2006), is 0.001 unit
of dUTPase activity under standard assay conditions for 1hour at 37 1C.
Cell culture
HEK293 cells stably expressing human TLR2 (Invivogen, San Diego,
CA) were maintained in DMEM-supplemented medium, as described
(Ariza et al., 2009). Human primary hDCs were purchased from
MatTek Corporation (Ashland, MA). hDCs were generated from
human umbilical cord blood CD34þ progenitor cells and
cultured using specially formulated medium, DC-100-MM (MatTek
Corporation), containing a cytokine cocktail designed to induce
differentiation of the CD34þ progenitor cells into dendritic
cells. These cells express key markers including CD1a, HLA-DR,
co-stimulatory molecules, Birbeck granules, and surface markers
characteristic of both plasmacytoid and myeloid dendritic cells
(Ayehunie et al., 2003). Normal human epidermal adult keratinocytes
(cat no. CC-2501A) were obtained from Lonza Biologics (Hopkinton,
MA) and maintained in KGM-2 medium.
Luciferase reporter gene assays
HEK293 cells (2.5 105) were seeded into 12-well plates and
24 hours later transiently transfected with 0.5 mg of pNFkB-Luc (a gift
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from Dr Douglas Golenbock, the University of Massachusetts Medical
School), 8 ng of pRL-TK reporter vectors (Promega, Madison, WI), or
with empty vector as described (Ariza et al., 2009). At 24–36 hours
after transfection, cells were treated with various concentrations of
purified HERV-K dUTPase (10 mgml1) for 8 hours or left untreated.
Zymosan (10 mgml1), a TLR2 ligand, was used as a positive control.
After treatment, cell lysates were prepared and reporter gene
activities were measured using the dual-luciferase reporter assay
system (Promega). Data were normalized for transfection efficiency
by measuring Renilla luciferase activity and expressed as mean
relative stimulation±SD.
Cytokine/chemokine proteome array
Primary hDCs and keratinocytes (3 105) were treated with
consensus HERV-K dUTPase or point/deletion mutation protein
variants (10mgml1) for 24 hours and the levels of 12 cytokines/
chemokines in cell supernatants of treated and control samples were
measured using SearchLight proteome arrays (Aushon BioSystems,
Billerica, MA). Briefly, samples were incubated for 1 hour on the
array plates that were pre-spotted with capture antibodies specific
for each protein biomarker. The bound proteins were detected using
a biotinylated detection antibody, followed by the addition of
streptavidin-horseradish peroxidase, and finally a chemiluminescent
substrate. The plates were immediately imaged using the SearchLight
imaging system, and data were analyzed using SearchLight Array
Analyst software. The amount of luminescent signal produced was
proportional to the amount of each protein present in the original
standard or sample. Concentrations are extrapolated off a standard
curve and represent the average±SD of an n of 4.
Statistical analysis
Statistical analyses were performed using a paired two-sample t-test
for the means. Results are shown as mean±SEM. Two-tailed
P-values have been reported when significant.
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